Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness
- 29 November 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 75 (4) , 682-689
Abstract
Background: The ability of antituberculosis drugs to cross the blood–brain barrier and reach the central nervous system is critical to their effectiveness in treating tuberculosis meningitis (TBM). We sought to fill a critical knowledge gap by providing data on the ability of new and repurposed antituberculosis drugs to penetrate into the cerebrospinal fluid (CSF). Methods: We conducted a clinical pharmacology study among patients treated for TBM in Tbilisi, Georgia, from January 2019 until January 2020. Serial serum and CSF samples were collected while patients were hospitalized. CSF was collected from routine lumbar punctures with the timing of the lumbar puncture alternating between 2 and 6 hours to capture early and late CSF penetration. Results: A total of 17 patients treated for TBM (8 with confirmed disease) were included; all received linezolid, with a subset receiving cycloserine (5), clofazimine (5), delamanid (4), and bedaquiline (2). All CSF measurements of bedaquiline (12), clofazimine (24), and delamanid (19) were below the limit of detection. The median CSF concentrations of cycloserine at 2 and 6 hours were 15.90 and 15.10 µg/mL with adjusted CSF/serum ratios of 0.52 and 0.66. CSF concentrations of linezolid were 0.90 and 3.14 µg/mL at 2 and 6 hours, with adjusted CSF/serum ratios of 0.25 and 0.59, respectively. CSF serum linezolid concentrations were not affected by rifampin coadministration. Conclusions: Based on moderate to high CSF penetration, linezolid and cycloserine may be effective drugs for TBM treatment, whereas the utility of bedaquiline, delamanid, and clofazimine is uncertain given their low CSF penetration.Keywords
Funding Information
- National Institutes of Health
- Fogarty International Center (D43 TW007124)
- National Institute of Allergy and Infectious Diseases (R03 AI139871, K23AI103044, K23 AI144040, TL1TR002382, UL1TR002378)
This publication has 27 references indexed in Scilit:
- Linezolid Manifests a Rapid and Dramatic Therapeutic Effect for Patients with Life-Threatening Tuberculous MeningitisAntimicrobial Agents and Chemotherapy, 2014
- Bedaquiline: a review of human pharmacokinetics and drug-drug interactionsJournal of Antimicrobial Chemotherapy, 2014
- Tuberculous meningitis: a uniform case definition for use in clinical researchThe Lancet Infectious Diseases, 2010
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System InfectionsClinical Microbiology Reviews, 2010
- Cerebrospinal fluid concentrations of antituberculosis agents in adults and childrenTuberculosis, 2010
- Evolution of Central Nervous System Multidrug-Resistant Mycobacterium tuberculosis and Late Relapse of Cryptic Prosthetic Hip Joint Tuberculosis: Complications during Treatment of Disseminated Isoniazid-Resistant Tuberculosis in an Immunocompromised HostJournal of Clinical Microbiology, 2009
- Effect of Antituberculosis Drug Resistance on Response to Treatment and Outcome in Adults with Tuberculous MeningitisThe Journal of Infectious Diseases, 2005
- The blood-brain barrier: Bottleneck in brain drug developmentNeuroRX, 2005
- Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone AntibacterialClinical Pharmacokinetics, 2003
- Multidrug-Resistant Tuberculous Meningitis: Clinical Problems and Concentrations of Second-Line Antituberculous MedicationsAnnals of Pharmacotherapy, 1999